Eagle Pharmaceuticals Bundle
Who Really Owns Eagle Pharmaceuticals?
Unraveling the ownership structure of a pharmaceutical company like Eagle Pharmaceuticals is crucial for understanding its strategic direction and future prospects. A shift in ownership can signal significant changes, especially in a dynamic industry. For investors and industry watchers, knowing who controls Eagle Pharmaceuticals is key to assessing its potential.
Founded in 2007 by Scott Tarriff, Eagle Pharmaceuticals, a Eagle Pharmaceuticals SWOT Analysis can provide deeper insight into the company's position, is a specialty pharmaceutical company focused on injectable products. With a market capitalization of approximately $29.95 million as of June 2025, understanding the evolution of Eagle Pharmaceuticals ownership, from its founder's initial stake to the influence of key investors, is vital. This exploration will delve into the key players shaping the future of this Pharmaceutical company.
Who Founded Eagle Pharmaceuticals?
The story of Eagle Pharmaceuticals begins with its founding in 2007 by Scott Tarriff. While the exact initial ownership structure isn't publicly detailed, Tarriff's role as President and CEO was crucial in the company's early development within the pharmaceutical industry.
The company's initial funding rounds set the stage for its future. Over three rounds, Eagle Pharmaceuticals raised a total of $12.3 million. This early financial backing from investors like ProQuest Investments and Swiss National Bank helped fuel the company's growth.
The transition from private to public ownership marked a significant milestone. Eagle Pharmaceuticals went public in 2014, listing its shares on the NASDAQ Global Market under the ticker symbol 'EGRX'. The initial public offering (IPO) priced shares at $15.00 each, providing a new avenue for investment and expanding the company's shareholder base.
Key Ownership Milestones
The early ownership of Eagle Pharmaceuticals involved key figures and significant financial events. The IPO in 2014 was a pivotal moment, changing the company's ownership dynamics. While specific details on early agreements like vesting schedules aren't available, these practices would have shaped early control.
- 2007: Founded by Scott Tarriff.
- February 14, 2011: First funding round.
- 2014: IPO on NASDAQ (EGRX).
- Early investors included ProQuest Investments and Swiss National Bank.
Eagle Pharmaceuticals SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Eagle Pharmaceuticals’s Ownership Changed Over Time?
The ownership structure of Eagle Pharmaceuticals has seen shifts since its initial public offering (IPO) on February 12, 2014. Understanding the growth strategy of Eagle Pharmaceuticals is crucial when examining its ownership dynamics. As of June 2025, the company's market capitalization is approximately $29.95 million, reflecting the current valuation and investor sentiment.
Major stakeholders in Eagle Pharmaceuticals include a mix of institutional investors, mutual funds, and individual insiders. These entities play a significant role in shaping the company's strategic direction. The evolution of ownership reflects the company's journey within the pharmaceutical industry.
| Ownership Category | May 2025 | March 2025 |
|---|---|---|
| Institutional Investors | 1.04% | 1.04% |
| Mutual Funds | 5.32% | 5.79% |
| Insider Holdings | 0.44% | 0.44% |
Key institutional shareholders in late 2024 and early 2025 included Nantahala Capital Management, LLC, which reported holding 4,945,209 shares (38.08% ownership) as of February 19, 2025, and Union Square Park Capital Management, LLC, holding 1,485,677 shares (11.44% ownership) as of February 14, 2025. Other institutional investors in early 2025 included AJOVista LLC, XTX Topco Ltd, Stanley-Laman Group, Ltd., Archer Investment Corp, and Acadian Asset Management LLC. These shifts in major shareholding, particularly the significant institutional ownership, can influence company strategy and governance by introducing diverse investment objectives and increased scrutiny on financial performance and management decisions.
Eagle Pharmaceuticals Ownership Overview
The ownership of Eagle Pharmaceuticals involves institutional investors, mutual funds, and insiders. Institutional investors held 1.04% of shares as of May 2025. Mutual funds held 5.32% in May 2025. Insider holdings remained at 0.44% in May 2025.
- Nantahala Capital Management, LLC held 38.08% as of February 19, 2025.
- Union Square Park Capital Management, LLC held 11.44% as of February 14, 2025.
- These key stakeholders influence the company's strategy and governance.
- Understanding the ownership structure is vital for investors.
Eagle Pharmaceuticals PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Eagle Pharmaceuticals’s Board?
The current Board of Directors of Eagle Pharmaceuticals is pivotal in guiding the company's governance and strategic direction. Michael Graves holds the position of Interim Executive Chairman of the Board, a role he undertook following the departure of founder Scott Tarriff in November 2023. Graves has been a member of the Board since November 2013 and has served as Chairman since June 2016. Other key figures in management include Christopher Krawtschuk as Director of Finance/CFO and Steven Ratoff as a Director/Board Member. Understanding the composition of the board is crucial for those looking into Eagle Pharmaceuticals ownership and its future trajectory within the pharmaceutical industry.
The board's decisions and oversight are essential for the company's performance. The leadership structure, with individuals like Graves and Krawtschuk, influences the company's strategic initiatives and financial health. The board's actions directly impact how the company navigates the competitive landscape and manages its resources. For investors and stakeholders interested in Eagle Pharmaceuticals company profile, the board's composition and actions are key indicators of the company's stability and potential for growth.
| Board Member | Title | Role |
|---|---|---|
| Michael Graves | Interim Executive Chairman | Oversees Board Activities |
| Christopher Krawtschuk | Director of Finance/CFO | Manages Financial Operations |
| Steven Ratoff | Director/Board Member | Provides Strategic Guidance |
The voting structure at Eagle Pharmaceuticals, like most public companies, typically follows a one-share-one-vote system for common stock. This means each share generally carries one vote on shareholder matters. In October 2024, the company adopted a limited duration stockholder rights plan. This plan, set to expire on October 30, 2025, aims to protect stockholder interests and prevent potential hostile takeovers. The adoption of such a plan reflects the company's commitment to safeguarding shareholder value, especially considering market fluctuations and external pressures. This is important context for anyone researching Eagle Pharmaceuticals stock ownership and the company's governance practices.
Voting Rights and Shareholder Protection
The voting structure at Eagle Pharmaceuticals is standard, with one vote per share. A stockholder rights plan was implemented in October 2024, expiring in October 2025.
- One-share-one-vote system.
- Rights plan to protect shareholder interests.
- Plan set to expire on October 30, 2025.
- These measures reflect the company's commitment to shareholder value.
Eagle Pharmaceuticals Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Eagle Pharmaceuticals’s Ownership Landscape?
Over the past few years, the ownership structure of Eagle Pharmaceuticals has seen notable shifts. A significant change occurred in November 2023 with the retirement of Scott Tarriff, the founder, President, and CEO. Michael Graves stepped in as Interim Executive Chairman. Furthermore, in March 2025, the company entered a $69 million royalty purchase agreement with Blue Owl Capital, which provided immediate capital. This transaction was intended to pay off credit agreements and support ongoing R&D programs.
Regarding ownership trends, institutional ownership has fluctuated. As of May 2025, institutional investors held 1.04% of the shares, and mutual funds held 5.32%, with insider holdings at 0.44%. In March 2025, institutional holdings were also 1.04%, while mutual fund holdings were slightly higher at 5.79%. The company's stock price experienced a decline, falling by 39.55% between June and October 2024. These details provide insight into Revenue Streams & Business Model of Eagle Pharmaceuticals.
| Metric | May 2025 | March 2025 |
|---|---|---|
| Institutional Ownership | 1.04% | 1.04% |
| Mutual Fund Ownership | 5.32% | 5.79% |
| Insider Holdings | 0.44% | N/A |
In October 2024, Eagle Pharmaceuticals adopted a limited duration stockholder rights plan, set to expire in October 2025. This action was taken to protect against potential unwanted changes in control, particularly given the stock price decline and external interest. Recent SEC filings in early 2025, including Schedule 13G/A filings in February 2025, provide further details on beneficial ownership. These developments highlight the ongoing evolution of Eagle Pharmaceuticals' ownership landscape.
Key Development
The retirement of the founder, President, and CEO in November 2023 and the appointment of an Interim Executive Chairman marked a significant leadership transition.
Financial Strategy
The royalty purchase agreement with Blue Owl Capital in March 2025 provided $69 million in non-dilutive capital to support debt repayment and R&D initiatives.
Ownership Stability
Institutional and insider ownership levels have remained relatively stable, while mutual fund holdings have seen slight fluctuations.
Defensive Measures
The adoption of a stockholder rights plan in October 2024 reflects efforts to protect against potential changes in company control.
Eagle Pharmaceuticals Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Eagle Pharmaceuticals Company?
- What is Competitive Landscape of Eagle Pharmaceuticals Company?
- What is Growth Strategy and Future Prospects of Eagle Pharmaceuticals Company?
- How Does Eagle Pharmaceuticals Company Work?
- What is Sales and Marketing Strategy of Eagle Pharmaceuticals Company?
- What is Brief History of Eagle Pharmaceuticals Company?
- What is Customer Demographics and Target Market of Eagle Pharmaceuticals Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.